Centessa Pharmaceuticals (CNTA) Shares Outstanding (2021 - 2026)

Centessa Pharmaceuticals (CNTA) has 6 years of Shares Outstanding data on file, last reported at $154.7 million in Q1 2026.

• Shares Outstanding for Q1 2026 came in at $154.7 million, up 15.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $154.7 million (up 15.85% YoY), and the FY2025 annual result was $149.2 million, up 12.51% from the prior year.
• Shares Outstanding grew to $154.7 million in Q1 2026 per CNTA's latest filing, from $149.2 million in the prior quarter.
• Over five years, Shares Outstanding peaked at $154.7 million in Q1 2026 and troughed at $94.3 million in Q2 2022.
• A 5-year average of $115.9 million and a median of $106.8 million in 2024 frame the typical range for Shares Outstanding.
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding soared 311.64% in 2022, then advanced 1.09% in 2023.
• A 5-year view of Shares Outstanding shows it stood at $94.8 million in 2022, then rose by 4.15% to $98.8 million in 2023, then surged by 34.28% to $132.6 million in 2024, then climbed by 12.51% to $149.2 million in 2025, then grew by 3.69% to $154.7 million in 2026.
• Business Quant data shows CNTA's Shares Outstanding at $154.7 million in Q1 2026, $149.2 million in Q4 2025, and $134.4 million in Q3 2025.